BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$80.91 USD
-1.26 (-1.53%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $80.92 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMRN 80.91 -1.26(-1.53%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Other News for BMRN
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth Potential
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
Biotech Alert: Searches spiking for these stocks today
BioMarin price target lowered by $2 at Canaccord, here's why
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)